Vaxalto Biotherapeutics and Mount Sinai Enter into Exclusive License Agreement for the Development and Commercialization of Novel Immunotherapeutic Oncolytic Viruses for Treatment of Cancer

Press/Media

Period4 Mar 2021

Media coverage

6

Media coverage